C. Sederholm

发表

A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.

J. von Pawel, N. Viñolas, C. Dittrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

L. Ek, R. Bremnes, B. Bergman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

G. Wagenius, O. Brodin, L. Ekberg, 2011, Lung cancer.

Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.

G. Hillerdal, K. Lamberg, S. Friesland, 2008, Anticancer research.

A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study

L. Ek, R. Bremnes, B. Bergman, 2007 .

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

R. Stahel, S. Ricci, J. von Pawel, 1999, Lung cancer.

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.

G. Hillerdal, K. Lamberg, K. Kölbeck, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.

Jan Nyman, Karl-Axel Johansson, Lars Ekberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.

R. Stahel, S. Ricci, P. Kellokumpu-Lehtinen, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

S. Ricci, J. von Pawel, P. Kellokumpu-Lehtinen, 1997, Seminars in oncology.

Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.

C. Sederholm, 2002, Seminars in oncology.

Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report.

T. Andersson, H. Hellquist, C. Sederholm, 1997, British Journal of Cancer.

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.

Bengt Bergman, Erik Holmberg, Lars Thaning, 2011, European journal of cancer.

Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.

G. Hillerdal, C. Sederholm, K. Andersson, 2011, Lung cancer.

Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Joint Lung Cancer Study Group.

L. Ek, K. Lamberg, M. Helsing, 1999, Lung cancer.

How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.

G. Wagenius, S. Friesland, J. Nyman, 2009, Lung cancer.

Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.

Jan Nyman, Karl-Axel Johansson, Lars Ekberg, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.

L. Ek, K. Lamberg, B. Bergman, 2013, European journal of cancer.

NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction

Jan Nyman, Lars Ekberg, Christer Sederholm, 2011, Acta oncologica.

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.

J. von Pawel, N. Viñolas, C. Dittrich, 2014, European journal of cancer.